REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: September 18, 2006
Last updated: June 28, 2012
Last verified: October 2010
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.

Condition Intervention Phase
Acute ST Elevation Myocardial Infarction
Drug: Epoietin Alfa
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Changes in infarct size, as assessed by magnetic resonance imaging [ Time Frame: within 2-6 days of administration of study medication ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • End-systolic volume, ejection fraction [ Time Frame: Within 2-6 days of administration of study medication, and 3 months later ] [ Designated as safety issue: No ]
  • Number of circulating endothelial progenitor cells [ Time Frame: Within 2-6 days of administration of study medication, and 3 months later ] [ Designated as safety issue: No ]
  • Changes in infarct size [ Time Frame: 3 months after administration of study medication ] [ Designated as safety issue: No ]
  • Change in hemoglobin levels [ Time Frame: During the first two weeks following study medication administration ] [ Designated as safety issue: Yes ]
  • Occurrence of death or arterial or venous thrombotic events [ Time Frame: Within 4 weeks following administration of study medication ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 250
Study Start Date: September 2005
Study Completion Date: January 2011
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 15,000 Units
Single parenteral administration
Drug: Epoietin Alfa
Experimental: 30,000 Units
Single parenteral administration
Drug: Epoietin Alfa
Experimental: 60,000 Units
Single parenteral administration
Drug: Epoietin Alfa
Placebo Comparator: Placebo
Single parenteral administration of saline placebo
Drug: Placebo

Detailed Description:
REVEAL is a randomized, double-blinded, placebo-controlled, parallel phase II clinical study that will evaluate the effects of erythropoietin administration on infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large myocardial infarctions (MI). The study will be conducted in two phases: a dose-escalation safety phase and a single dose efficacy phase. Eligible patients who present to the hospital with an acute ST-elevation MI and who agree to participate in this study will be randomly assigned to receive a single infusion of study medication consisting either of erythropoietin or placebo. The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging (MRI) within 2-6 days of the infusion of the study medication, and again approximately 3 months later.

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Age greater than 21 years

Acute ST-elevation myocardial infarction

Referral for primary or rescue angioplasty

Revascularization procedure within 8 hours from the onset of ischemic symptoms

TIMI (Thrombolysis in myocardial infarction) flow grade 0 or 1 in the culprit coronary artery at the beginning of coronary angiography

Successful revascularization of infarct-related artery


Clinical indication for erythropoietin

STEMI (ST-elevation myocardial infarction) due to occlusion of a branch vessel

Any history of prior MI, PCI (Percutaneous coronary intervention), CABG (Coronary artery bypass graft), cardiomyopathy, myocarditis, or CHF (congestive heart failure)

Hypersensitivity to human albumin, mammalian cell-derived products, or erythropoietin

Hematocrit greater than 42% in men or greater than 40% in women at the time of study drug administration

Uncontrolled hypertension at the time of study drug administration

Cardiogenic shock

Need for coronary surgical revascularization as determined at the time of the index coronary catheterization

History of hypercoagulable disorder, thromboembolic event, or venous thrombosis

History of stroke or TIA (transient ischemic attack)

History of seizures

Contraindication to MRI

Pregnancy or nursing mother

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00378352

United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Florida
University of Miami, School of Medicine
Miami, Florida, United States, 33136
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073-6769
United States, Minnesota
Mayo Clinic, Rochester
Rochester, Minnesota, United States, 55905
United States, New York
New York Methodist Hospital
Brooklyn, New York, United States, 11215
Cornell University
New York, New York, United States, 10021-4872
NY Presbyterian Hospital
New York, New York, United States, 10021
Weill Medical College
New York, New York, United States, 10021
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Wake Forest University
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Penn State Heart and Vascular Institute
Hershey, Pennsylvania, United States, 17033
United States, Tennessee
Nashville Cardiovascular Magnetic Resonance Institute
Brentwood, Tennessee, United States, 37027
United States, Virginia
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
National Institute on Aging (NIA)
Principal Investigator: Edward G Lakatta, M.D. National Institute on Aging (NIA)
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Edward G. Lakatta, M.D./National Institute on Aging, National Institutes of Health Identifier: NCT00378352     History of Changes
Other Study ID Numbers: 999905255  05-AG-N255 
Study First Received: September 18, 2006
Last Updated: June 28, 2012
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Acute Myocardial Infarction
Left Ventricular Remodeling
Cardiac Magnetic Resonance Imaging
Endothelial Progenitor Cells
Infarct Size

Additional relevant MeSH terms:
Myocardial Infarction
Ventricular Remodeling
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Pathologic Processes
Pathological Conditions, Anatomical
Vascular Diseases
Epoetin Alfa
Hematinics processed this record on May 26, 2016